Skip to content

Climb Bio, Inc. CLYM Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Amgen logo
AmgenAMGN
1.3×+0.1×
Vera Therapeutics logo
Vera TherapeuticsVERA
13.6×-14.0×
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
8.1×+0.7×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
14.3×-17.7×

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×

Where this comes from

Calculated from Climb Bio, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s current ratio?
Climb Bio, Inc. (CLYM) reported current ratio of 27.9× in Q1 2026.
How has Climb Bio, Inc.'s current ratio changed year-over-year?
Climb Bio, Inc.'s current ratio increased by 95.5% year-over-year, from 14.3× to 27.9×.
What is the long-term trend for Climb Bio, Inc.'s current ratio?
Over 5 years (2020 to 2025), Climb Bio, Inc.'s current ratio has grown at a 16.1% compound annual growth rate (CAGR), from 7.2× to 15.2×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.